Compare MLSS & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLSS | RNXT |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.6M | 42.4M |
| IPO Year | 1996 | 2021 |
| Metric | MLSS | RNXT |
|---|---|---|
| Price | $0.47 | $2.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.00 | ★ $8.25 |
| AVG Volume (30 Days) | 158.0K | ★ 824.2K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,973,982.00 | $1,123,000.00 |
| Revenue This Year | $12.64 | $194.66 |
| Revenue Next Year | $8.99 | $279.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.99 | ★ 2511.63 |
| 52 Week Low | $0.22 | $0.70 |
| 52 Week High | $0.64 | $2.20 |
| Indicator | MLSS | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 50.73 | 85.55 |
| Support Level | $0.24 | $0.83 |
| Resistance Level | $0.48 | N/A |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 31.90 | 96.85 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.